Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.

@article{Deacon2010LinagliptinAX,
  title={Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.},
  author={Carolyn F Deacon and Jens Juul Holst},
  journal={Expert opinion on investigational drugs},
  year={2010},
  volume={19 1},
  pages={133-40}
}
IMPORTANCE OF THE FIELD Type 2 diabetes is a progressive disease for which current treatments are often unsatisfactory with respect to achieving therapeutic goals and unwanted side effects. AREAS COVERED Preclinical and clinical studies of linagliptin, a new oral antidiabetic agent, including data presented at Scientific Meetings and peer-reviewed studies published since 2007. WHAT THE READER WILL GAIN This article reviews pharmacokinetic and pharmacodynamic characteristics of linagliptin… CONTINUE READING
58 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…